TPC
RANI icon

Takeda Pharmaceutical Company’s Rani Therapeutics RANI Stock Holding History

Takeda Pharmaceutical Company’s Portfolio RANI Stock Details RANI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$102K Hold
203,190
– – 0.62% 7
2025
Q2 		$104K Hold
203,190
– – 0.53% 10
2025
Q1 		$256K Hold
203,190
– – 1.58% 9
2024
Q4 		$278K Hold
203,190
– – 1.05% 10
2024
Q3 		$439K Sell
203,190
-11,982
-6% -$34.3K 1.16% 9
2024
Q2 		$818K Sell
215,172
-123,507
-36% -$640K 0.35% 10
2024
Q1 		$1.05M Hold
338,679
– – 0.36% 12
2023
Q4 		$1.12M Buy
+338,679
New +$783K 0.34% 10

Other funds holding RANI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $851M AUM 5.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Takeda Pharmaceutical Company's RANI Position: Q3 2025 in Review

Takeda Pharmaceutical Company held its Rani Therapeutics (RANI) position steady in Q3 2025 at 203,190 shares worth $102K. The position accounts for 0.62% of the portfolio, ranked #7.

Takeda Pharmaceutical Company first reported a position in RANI in Q4 2023 and has held it in 8 quarters since. The position peaked at $1.12M in Q4 2023. 38 funds tracked by Wall St. Rank hold RANI as of Q3 2025.

  • Takeda Pharmaceutical Company held 203,190 shares of Rani Therapeutics worth $102K as of Q3 2025.
  • Takeda Pharmaceutical Company left its Rani Therapeutics share count unchanged in Q3 2025.
  • Rani Therapeutics made up 0.62% of Takeda Pharmaceutical Company's portfolio in Q3 2025, its #7 holding.
  • Takeda Pharmaceutical Company first reported a position in Rani Therapeutics in Q4 2023 and has held it in 8 quarters since.
  • Takeda Pharmaceutical Company's Rani Therapeutics position peaked at $1.12M in Q4 2023.
  • 38 funds tracked by Wall St. Rank held Rani Therapeutics as of Q3 2025.

Based on Takeda Pharmaceutical Company's 13F filing for Q3 2025, filed 13 Nov 2025.